David Epstein, Seagen CEO
August 3, 2023 11:07 AM EDTUpdated 01:22 PM
Deals

Up­dat­ed: Seagen de­pri­or­i­tizes an­ti­body-drug can­di­date from $4.2B Mer­ck deal

Lei Lei Wu

News Reporter

Seagen has de­pri­or­i­tized work on ladi­ratuzum­ab ve­dotin, the biotech qui­et­ly dis­closed in its sec­ond quar­ter fi­nan­cial re­port Wednes­day.

Seagen has been …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

2024's bio­phar­ma win­ners and losers; Ca­griSe­ma falls short; Mer­ck swings Chi­na GLP-1 deal; and more

A service from the Financial Times